Clinical Trial Update: IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Immatics Biotechnologies reports its TCER molecule IMA402 is being evaluated in Phase 1/2 trials for recurrent and/or refractory solid tumors and is currently r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Solid Tumors

Drugs mentioned

• IMA402 (IMA402)

Snippet

Sponsor: Immatics Biotechnologies GmbH | Conditions: Refractory Cancer, Recurrent Cancer | Phase 1, Phase 2 | Status: RECRUITING